Safety evaluation of chemically modified beta‐lactoglobulin administered intravaginally

Currently, there is no specific antiviral therapy for treatment of HPV infection. Jiang and colleagues previously reported that anhydride‐modified proteins have inhibitory activities against multiple viruses including HPV. Here, we evaluated the safety of 3‐hydroxyphthalic anhydride‐modified bovine beta‐lactoglobulin, designated JB01, vaginally applied in women infected by high‐risk HPV. After the vaginal application of JB01 in 38 women for 3 months, no serious adverse events were reported, and normalization of the vaginal micro‐environment has been observed. It can be concluded that JB01‐BD is safe for vaginal use in HPV‐infected women, suggesting its potential application for the treatment of HPV infection. J. Med. Virol. 88:1098–1101, 2016 . © 2015 Wiley Periodicals, Inc.